OpenLB
Open Library of Bioscience
Advanced Search
Veterinary sciences
Jan 31, 2022;9 (2):

The Translational Role of Animal Models for Estrogen-Related Functional Bladder Outlet Obstruction and Prostatic Inflammation.

Risto Santti, Emrah Yatkin, Jenni Bernoulli, Tomi Streng
Author Information
  1. Risto Santti: Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland.
  2. Emrah Yatkin: Central Animal Laboratory, University of Turku, FI-20014 Turku, Finland.
  3. Jenni Bernoulli: Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland.
  4. Tomi Streng: Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland.
PMID: 35202312 DOI: 10.3390/vetsci9020060

Abstract

The prevalence of LUTS and prostatic diseases increases with age both in humans and companion animals, suggesting that a common underlying cause of these conditions may be age-associated alterations in the balance of sex hormones. The symptoms are present with different and variable micturition dysfunctions and can be assigned to different clinical conditions including Bladder Outlet Obstruction (BOO). LUTS may also be linked to chronic non-bacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS), but the relationship between these conditions is unknown. This review summarizes the preclinical data that supports a role for excessive estrogen action in the development of obstructive voiding and nonbacterial prostatic inflammation. Preclinical studies that are emphasized in this review have unequivocally indicated that estrogens can induce functional and structural changes resembling those seen in human diseases. Recognizing excessive estrogen action as a possible hormonal basis for the effects observed at multiple sites in the LUT may inspire the development of innovative treatment options for human and animal patients with LUTS associated with functional BOO and CP/CPPS.

Keywords

animal models bladder outlet obstruction estradiol to testosterone ratio lower urinary tract symptoms prostatic inflammation

References

  1. Neurourol Urodyn. 2017 Apr;36(4):894-901 [PMID: 28444709]
  2. Urology. 2008 Feb;71(2):261-6 [PMID: 18308097]
  3. Neurourol Urodyn. 2011 Jun;30(5):708-13 [PMID: 21661018]
  4. J Urol. 1999 Jul;162(1):142-6 [PMID: 10379758]
  5. J Urol. 2017 Jul;198(1):122-128 [PMID: 28089730]
  6. Toxicol Appl Pharmacol. 1996 Feb;136(2):211-9 [PMID: 8619228]
  7. J Urol. 1988 Nov;140(5):1049-53 [PMID: 3172358]
  8. J Urol. 1996 Dec;156(6):2098-103 [PMID: 8911398]
  9. Eur Urol. 1992;22(2):123-9 [PMID: 1478227]
  10. J Clin Endocrinol Metab. 2004 Dec;89(12):6039-47 [PMID: 15579756]
  11. Prostate. 1991;18(2):117-29 [PMID: 2006118]
  12. Urology. 2008 Mar;71(3):475-9; discussion 479 [PMID: 18342190]
  13. Br J Urol. 1988 Oct;62(4):326-30 [PMID: 3056566]
  14. J Urol. 2007 Sep;178(3 Pt 1):896-900; discussion 900-1 [PMID: 17632164]
  15. J Clin Invest. 1983 May;71(5):1114-23 [PMID: 6189857]
  16. Urology. 1996 Jun;47(6):836-9 [PMID: 8677573]
  17. J Urol. 1995 Mar;153(3 Pt 1):689-93 [PMID: 7532234]
  18. BJU Int. 2018 Jan;121(1):130-138 [PMID: 28941035]
  19. BJU Int. 2001 Jun;87(9):797-805 [PMID: 11412216]
  20. Vet Immunol Immunopathol. 2001 Feb 10;78(3-4):297-303 [PMID: 11292530]
  21. J Urol. 2000 Apr;163(4):1304-8 [PMID: 10737534]
  22. Prostate Cancer Prostatic Dis. 2007;10(1):15-29 [PMID: 17199136]
  23. J Urol. 2001 Apr;165(4):1305-9 [PMID: 11257706]
  24. Can Urol Assoc J. 2018 Jun;12(6):196-202 [PMID: 29485036]
  25. J Urol. 1976 Oct;116(4):493-5 [PMID: 1053342]
  26. J Pharmacol Exp Ther. 2008 Oct;327(1):58-67 [PMID: 18583549]
  27. J Urol. 2002 Jul;168(1):298-302 [PMID: 12050560]
  28. PLoS One. 2014 Aug 15;9(8):e104395 [PMID: 25127394]
  29. BJU Int. 2003 Dec;92(9):972-6 [PMID: 14632858]
  30. Eur Urol. 2015 Jun;67(6):1099-1109 [PMID: 25613154]
  31. Mol Cell Endocrinol. 2000 Jun;164(1-2):109-16 [PMID: 11026563]
  32. J Urol. 1994 Dec;152(6 Pt 1):2063-5 [PMID: 7966675]
  33. J Urol. 2001 Aug;166(2):674-7 [PMID: 11458115]
  34. Int J Androl. 2009 Aug;32(4):399-410 [PMID: 19515173]
  35. Urology. 1997 Nov;50(5):700-3 [PMID: 9372878]
  36. PLoS One. 2018 Aug 2;13(8):e0201912 [PMID: 30071117]
  37. J Urol. 1982 May;127(5):958-63 [PMID: 7087000]
  38. Prostate. 1988;12(3):271-86 [PMID: 2453862]
  39. BJU Int. 2015 Oct;116(4):509-25 [PMID: 25711488]
  40. Exp Biol Med (Maywood). 2007 May;232(5):674-81 [PMID: 17463164]
  41. J Urol. 1981 Apr;125(4):542-4 [PMID: 7218456]
  42. Inflamm Res. 2009 Dec;58(12):829-36 [PMID: 19757087]
  43. Andrology. 2020 Jan;8(1):101-109 [PMID: 31090261]
  44. Urology. 2000 Mar;55(3):397-402 [PMID: 10699620]
  45. Andrology. 2016 Jul;4(4):684-94 [PMID: 27230799]
  46. Practitioner. 2016 Apr;260(1792):11-6, 2 [PMID: 27337754]
  47. Prostate. 2008 Sep 1;68(12):1296-306 [PMID: 18500685]
  48. Transl Androl Urol. 2016 Dec;5(6):890-897 [PMID: 28078221]
  49. J Urol. 1993 Aug;150(2 Pt 1):351-8 [PMID: 7686980]
  50. Eur Urol. 2008 Dec;54(6):1379-84 [PMID: 18036719]
  51. BMC Vet Res. 2013 Oct 08;9:197 [PMID: 24099564]
  52. J Clin Endocrinol Metab. 2002 Feb;87(2):589-98 [PMID: 11836290]
  53. J Sex Med. 2010 Aug;7(8):2698-713 [PMID: 20412431]
  54. BJU Int. 2005 Nov;96(7):1126-30 [PMID: 16225541]
  55. Neurourol Urodyn. 1998;17(3):263-71 [PMID: 9590478]
  56. J Urol. 1995 Aug;154(2 Pt 1):391-5 [PMID: 7541852]
  57. Urology. 2003 Jan;61(1):37-49 [PMID: 12559262]
  58. Prostate. 2008 May 15;68(7):728-39 [PMID: 18302197]
  59. J Urol. 1986 May;135(5):972-6 [PMID: 3959251]
  60. J Urol. 2002 Nov;168(5):2263-8 [PMID: 12394772]
  61. Neurourol Urodyn. 2001;20(5):601-21 [PMID: 11574937]
  62. Differentiation. 2021 Mar-Apr;118:72-81 [PMID: 33478774]
  63. J Urol. 2001 Feb;165(2):683-7 [PMID: 11176458]
  64. J Urol. 1981 Apr;125(4):545-8 [PMID: 7218457]
  65. J Urol. 1982 May;127(5):953-7 [PMID: 7086999]
  66. Am J Pathol. 2004 Mar;164(3):1039-48 [PMID: 14982857]
  67. Prostate. 1994;24(2):67-78 [PMID: 7508622]
  68. J Urol. 2002 Jan;167(1):137-40 [PMID: 11743292]
  69. J Urol. 1984 Sep;132(3):474-9 [PMID: 6206240]
  70. Auton Neurosci. 2001 Jan 14;86(3):208-15 [PMID: 11270099]
  71. Adv Exp Med Biol. 2019;1124:149-167 [PMID: 31183826]
  72. J Urol. 2014 Jan;191(1):130-7 [PMID: 23770136]
  73. Neurourol Urodyn. 2011 Jun;30(5):636-46 [PMID: 21661007]
  74. Urol Int. 1991;46(1):55-7 [PMID: 2024373]
  75. Neurourol Urodyn. 2001;20(2):197-210; discussion 210-3 [PMID: 11170194]
  76. Rev Urol. 2005;7 Suppl 6:S14-21 [PMID: 16986024]
  77. Biomed Res Int. 2014;2014:906921 [PMID: 24877147]
  78. Urology. 2007 Apr;69(4):708-13 [PMID: 17445656]
  79. Ciba Found Symp. 1990;151:195-206; discussion 207-13 [PMID: 2226060]
  80. Fam Pract. 2001 Jun;18(3):328-32 [PMID: 11356743]
  81. Duodecim. 1990;106(18):1242-8 [PMID: 1670552]
  82. Vet Pathol. 1990 Sep;27(5):347-53 [PMID: 1700534]
  83. Prostate. 2007 Jun 1;67(8):888-99 [PMID: 17440979]
Journal Article Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0LUTSprostaticconditionsmaydiseasessymptomsdifferentcanbladderoutletobstructionBOOCP/CPPSreviewexcessiveestrogenactiondevelopmentinflammationfunctionalhumananimalprevalenceincreasesagehumanscompanionanimalssuggestingcommonunderlyingcauseage-associatedalterationsbalancesexhormonespresentvariablemicturitiondysfunctionsassignedclinicalincludingalsolinkedchronicnon-bacterialprostatitis/chronicpelvicpainsyndromerelationshipunknownsummarizespreclinicaldatasupportsroleobstructivevoidingnonbacterialPreclinicalstudiesemphasizedunequivocallyindicatedestrogensinducestructuralchangesresemblingseenRecognizingpossiblehormonalbasiseffectsobservedmultiplesitesLUTinspireinnovativetreatmentoptionspatientsassociatedTranslationalRoleAnimalModelsEstrogen-RelatedFunctionalBladderOutletObstructionProstaticInflammationmodelsestradioltestosteroneratiolowerurinarytract

Similar Articles

Cited By (1)